Special Issue "Small Molecules Targeting Protein-Protein Interactions (PPIs): Current Strategies for the Development of New Drugs"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 31 May 2022.

Special Issue Editor

Dr. Sachin P. Patil
E-Mail Website
Guest Editor
School of Engineering, Widener University, Chester, PA 19013, USA
Interests: Alzheimer's disease; cancer; coronary heart disease; immune checkpoints; interactome engineering; P53-MDM2 Inhibitors; PD-1/PD-L1 Inhibitors and enhancers; virtual screening; docking, molecular dynamics; machine learning

Special Issue Information

Dear Colleagues,

Protein–Protein Interactions (PPIs) are key cellular effectors regulating and executing the majority of the important biological functions in living organisms, including humans. Accordingly, PPIs represent a vast source of novel therapeutic targets, with the size of the human interactome reaching an estimated number of over 300,000 interactions and counting. This is welcome news in light of the disappointingly well-known decrease in drug discovery and development efficiency over the years, primarily due to the exhaustion of effective targets for traditional drug design that focuses on single proteins as opposed to PPIs.

To date, the Interactome Engineering through PPI modulation has been under the realm of primarily large biotherapeutics including monoclonal antibodies, protein fragments and macrocyclic peptides. The small-molecule tractability of PPIs, however, is on the rise, with the first such small-molecule drugs entering clinical trials recently, providing the much-needed impetus for this traditionally challenging area of research.

The journal Pharmaceuticals aims to highlight successes, challenges and emerging opportunities in this field, with particular emphasis on the various strategies, both experimental and computational, being utilized for the development of small-molecule modulators of clinically relevant PPIs. Both small-molecule inhibitors as well as stabilizers of PPIs are of importance.

We look forward to your contribution.

Dr. Sachin P. Patil
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • protein–protein interaction (PPIs)
  • PPI modulation
  • PPI inhibitors
  • PPI stabilizers
  • drug discovery and design
  • small molecule drugs

Published Papers

This special issue is now open for submission.
Back to TopTop